Owing to the propensity for visual loss, immunosuppressive treatment in the form of systemic and/or local therapy is often required for the management of noninfective intermediate and posterior ...

An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.

An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...

An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Treatment with a single intravitreal injection of Yutiq can significantly reduce recurrence rates of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Durasert, a 3-year treatment for posterior segment ...

PSivida Corp. announced Wednesday that its posterior uveitis drug Medidur had met its primary efficacy endpoint in a Phase 3 trial, with positive topline results from 129 participants. Randomized, ...

Posterior segment non-infectious uveitis (NIPU) is a chronic, inflammatory disease affecting the posterior segment of the eye, often involving the retina, and is a leading cause of blindness in ...

Uveitis is a rare inflammatory eye disease. Posterior and panuveitis in particular are associated with a poor prognosis and a protracted course of the disease. Diagnosis and monitoring can be ...

It is rare for patients with chronic lymphocytic leukemia (CLL) to present with ocular involvement, but a mutational test could help clinicians identify patients more quickly. Testing for myeloid ...

Expert Rev Ophthalmol. 2008;3(4):449-456. Infliximab is a monoclonal human-murine chimeric antibody. Since it is a chimeric antibody, infliximab is usually given concomitantly with a second agent, ...